AstraZeneca’s antibody therapy prevents Covid, study shows

A

AstraZeneca’s new antibody therapy reduced the risk of people developing Covid-19 symptoms by 77% in a late-stage trial, putting the drugmaker on track to offer protection to those who respond poorly to vaccines.

The company said on Friday that 75% of the participants in the trial for the therapy – two types of antibodies discovered by Vanderbilt University Medical Center – had chronic conditions including some with a lower immune response to vaccinations.

Similar therapies made with a drug class called monoclonal antibodies which mimic naturally occurring immune system proteins are being developed by Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir.

https://www.cnbc.com/2021/08/20/astrazenecas-antibody-therapy-prevents-covid-study-shows.html

WANT MORE POSITIVE NEWS?